KLS Keeping Law Simple Legislation in plain English

Straight-ahead summaries built from the official bill text. We keep the source links front and center and leave the decision up to you.

Back to Missouri

SB1581 • 2026

Establishes the "Veterans Mental Health Innovation Act" relating to ibogaine treatment

Establishes the "Veterans Mental Health Innovation Act" relating to ibogaine treatment

Healthcare
Passed Legislature

This bill passed both chambers and reached final enrollment, even if later executive action is not shown here.

Sponsor
Bean, Jason; House handler: N/A
Last action
2026-04-01
Official status
Voted Do Pass S Veterans and Military Affairs Committee
Effective date
2026-08-28

Plain English Breakdown

The plain English breakdown is still being put together. The official documents below are already here.

Bill History

  1. 2026-04-01 Missouri House of Representatives and Missouri Senate

    Voted Do Pass S Veterans and Military Affairs Committee

  2. 2026-03-03 Missouri House of Representatives and Missouri Senate

    Hearing Conducted S Veterans and Military Affairs Committee

  3. 2026-02-05 S309

    Second Read and Referred S Veterans and Military Affairs Committee

  4. 2026-01-20 S202

    S First Read

Official Summary Text

The following summaries of this bill are available:

Print All Summaries

Introduced

Print

SB 1581 - This act establishes the "Veterans Mental Health Innovation Act". Under this act, the Department of Health and Senior Services shall, subject to appropriation, award grants to conduct certified clinical drug development trials overseen by the U.S. Food and Drug Administration (FDA) on the use of ibogaine for the treatment of opioid use disorder, co-occurring substance use disorder, or any other neurological or mental health condition for which ibogaine demonstrates efficacy. Grantees shall meet the eligibility requirements set forth in the act, including having signed an agreement with a consortium established by another state that has submitted specified applications and requests with the FDA.

This act creates the "Ibogaine Study Fund" in the state treasury for the disbursement of grants under this act. Selected grant applicants shall submit quarterly reports to the Department and the Department shall submit an annual report to the General Assembly on the progress of the trials.

This act also creates the "Ibogaine Intellectual Property Fund" for all revenue attributable to all intellectual property rights and other commercial rights that may arise from drug development clinical trials conducted by a multistate consortium under this act during the period for which the trials are funded and any following period of commercialization. The moneys in the fund shall be used solely for programs that assist veterans or other at-risk populations in this state.

If ibogaine is approved by the FDA to treat a medical condition, only a licensed physician shall prescribe it for a patient and a licensed physician shall supervise its administration at a hospital or other licensed health care facility.

The Department shall begin accepting grant applications before November 1, 2026, but may delay implementation of some or all of the provisions of this act if the Department determines that a waiver or authorization from a federal agency is first necessary.

This act is identical to HB 2961 (2026).
SARAH HASKINS